Copyright © 2019. Inderes Oy. All rights reserved.

Genovis AB

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
11.2.
2021

Report for the fourth quarter of 2020          

Tiedotteet
10.12.
2020

Genovis AB and Glykos Finland Oy have today entered into a licensing and supply agreement for state-of-the-art linker-payload technologies to be combined with the site-specific antibody conjugation platform offered by Genovis.

Tiedotteet
5.11.
2020
July - September in brief
  • Net sales totaled SEK 14,216 (24,279) thousand.
Tiedotteet
13.8.
2020
April - June in brief
  • Net sales rose by 35 percent to SEK 15,490 (11,509) thousand.

Genovis AB

Genovis AB

Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.